ID   JK-1
AC   CVCL_2079
SY   JK1
DR   CLO; CLO_0007026
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473358
DR   BioSample; SAMN10988504
DR   cancercelllines; CVCL_2079
DR   Cell_Model_Passport; SIDM01727
DR   Cosmic; 787494
DR   Cosmic; 924046
DR   Cosmic; 1012071
DR   DepMap; ACH-000241
DR   DSMZ; ACC-347
DR   DSMZCellDive; ACC-347
DR   GEO; GSM887184
DR   GEO; GSM888257
DR   LiGeA; CCLE_718
DR   PharmacoDB; JK1_707_2019
DR   Progenetix; CVCL_2079
DR   Wikidata; Q54898958
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2169992;
RX   PubMed=10071072;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20809971;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=2169992); ~50 hours (DSMZ=ACC-347).
CC   HLA typing: A*31:01,31:01; B*15:11,58:01; C*03:02,03:02; DQA1*02:01,05:02; DQB1*06:04,06:04; DRB1*13:02,14:05 (PubMed=26589293).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=74.72%; East Asian, South=25.28%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9,13
ST   D16S539: 9,13
ST   D18S51: 14,19
ST   D19S433: 14
ST   D21S11: 29,31
ST   D2S1338: 17,19
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 13
ST   D8S1179: 12,13
ST   FGA: 21,25
ST   Penta D: 11,14
ST   Penta E: 16,18
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2169992; DOI=10.1002/1097-0142(19901001)66:7<1544::AID-CNCR2820660719>3.0.CO;2-9;
RA   Okuno Y., Suzuki A., Ichiba S., Takahashi T., Nakamura K., Hitomi K.,
RA   Sasaki R., Tada K., Imura H.;
RT   "Establishment of an erythroid cell line (JK-1) that spontaneously
RT   differentiates to red cells.";
RL   Cancer 66:1544-1551(1990).
//
RX   PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20809971; DOI=10.1186/1755-8166-3-15;
RA   Virgili A., Nacheva E.;
RT   "Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in
RT   chronic myeloid leukaemia: a FISH mapping study of CML patients and
RT   cell lines.";
RL   Mol. Cytogenet. 3:15.1-15.12(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//